| Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension. | |
| | |
MedLine Citation:
|
PMID: 18202666 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: To explore the effect of short-term cholesterol-lowering treatment with atorvastatin on erythrocyte sodium-lithium countertransport (Na(+)/Li(+) CT) activity. METHODS: Group A consisted of 30 patients (14 men) with mild essential hypertension (systolic blood pressure (SBP), 140-159 mm Hg and/or diastolic BP, 90-99 mm Hg) and primary hypercholesterolemia low-density lipoprotein (LDL) cholesterol >4.1 mmol/l and triglycerides (TG) <2.8 mmol/l), group B of 30 normotensive patients (16 men) with primary hypercholesterolemia, while 37 (18 men) healthy volunteers comprised the control group. After a 6-week dietary lead-in, all eligible patients were prescribed 20 mg/day of atorvastatin. Anthropometric data, blood-pressure (BP) measurements and determinations of lipid, non-lipid metabolic parameters (including homeostasis model assessment index, (HOMA-IR)) and erythrocyte Na(+)/Li(+) CT activity were collected at baseline and after 12 weeks of treatment. RESULTS: At baseline Na(+)/Li(+) CT activity was significantly higher in group A and B compared with the control group and correlated directly with obesity indices, systolic and diastolic BP, total cholesterol, LDL-cholesterol, TG, apolipoprotein B (apoB), HOMA-IR, uric acid and inversely with high-density lipoprotein (HDL)-cholesterol and apoA1. Systolic and diastolic BP levels, HOMA-IR and Na(+)/Li(+) CT activity were significantly decreased after atorvastatin treatment in both patient groups. The reduction in Na(+)/Li(+) CT activity correlated with baseline Na(+)/Li(+) CT activity and the changes in HOMA-IR values. CONCLUSIONS: Short-term treatment with atorvastatin for patients with hypercholesterolemia, and with or without essential hypertension, is associated with a significant reduction in the erythrocyte Na(+)/Li(+) CT activity, BP levels and insulin resistance independent of concomitant changes in lipid parameters. |
| | |
Authors:
|
Maria S Kosmidou; Apostolos I Hatzitolios; Alexandra Adamidou; Sotirios Giannopoulos; Nikolaos Raikos; George Parharidis; Haralampos J Milionis |
Related Documents
:
|
22379196 - Cardiopulmonary effects of using carbon dioxide for laparoscopic surgery in cats. 1985406 - Inverse correlation between plasma vitamin e and mortality from ischemic heart disease ... 3186476 - Genetics or environment? type a behavior and cardiovascular risk factors in twin children. 1981076 - Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: ha... 10696286 - Normal equine gastroduodenal secretion and motility. 16879466 - Positive end-expiratory pressure optimization using electric impedance tomography in mo... |
Publication Detail:
|
Type: Comparative Study; Controlled Clinical Trial; Journal Article Date: 2008-01-17 |
Journal Detail:
|
Title: American journal of hypertension Volume: 21 ISSN: 0895-7061 ISO Abbreviation: Am. J. Hypertens. Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-03-03 Completed Date: 2008-07-01 Revised Date: 2009-02-24 |
Medline Journal Info:
|
Nlm Unique ID: 8803676 Medline TA: Am J Hypertens Country: United States |
Other Details:
|
Languages: eng Pagination: 303-9 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Aristotle University, AHEPA Hospital, Thessaloniki, Greece. mkosmidou@uhi.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anticholesteremic Agents / pharmacology*, therapeutic use Biological Transport / drug effects Blood Pressure / drug effects Cholesterol / blood Dose-Response Relationship, Drug Erythrocytes / metabolism*, pathology Female Heptanoic Acids / pharmacology*, therapeutic use Humans Hyperlipidemias / drug therapy, metabolism*, pathology Hypertension / metabolism*, pathology Insulin Resistance Linear Models Lithium / metabolism* Male Middle Aged Pyrroles / pharmacology*, therapeutic use Sodium / metabolism* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin; 57-88-5/Cholesterol; 7439-93-2/Lithium; 7440-23-5/Sodium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin.
Next Document: Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients wi...